CAS：515814-01-4
chemical formula：C63H111N11O12

1. Specifications, usage, and dosage
Specification: Soft capsules: 7.9mg.
Usage and Dosage: For standard doses, one tablet should be taken twice a day.
2. Indications
Indications: An immunosuppressive calcineurin inhibitor used in combination with background immunosuppressive therapy for the treatment of adult patients with active lupus nephritis (LN).
3. Product advantages
A novel immunosuppressive agent for the treatment of adult systemic lupus nephritis (LN), developed by Aurinia Pharma in Canada and approved by the US FDA in January 2021, is the first drug targeting LN in the United States;
It is an improved cyclosporine analog, which has a similar structure and mechanism of action to cyclosporine A, but has higher efficacy and lower toxicity. Compared with cyclosporine, vocyclosporine also has the advantage of less impact on cholesterol and triglycerides, and lower risk of diabetes;
According to the 2020 disease guidelines, there are approximately one million patients with lupus erythematosus in China, of which 46% to 77% are complicated with lupus nephritis, and this disease is a controlled medication that requires long-term use;
The soft capsule formulation is the 66th batch reference, with no compound patent barriers. Currently, the original research has been clinically conducted in China, and it is highly likely to be declared as Class 4.

For more details, pls contact us:
Email: tonghuiyy218@upharm.cn
Wechat/Whatsapp:(+86)18922120635
Web: www.chinadrugservices.com